[68Ga]Ga-ABY-025 has been clinically tested, demonstrating a lower absorbed dose compared to FDG [74] and effectively differentiating HER2 positivity, particularly through the TBR (optimally tumor-to-spleen ratio) [75]. The gene discussed is ERBB2; the disease is neoplasm.